Valuation: CanSino Biologics Inc.

Market Cap 11.22B 13.23B 1.69B 1.51B 1.39B 1.26B 2.35B 160B 2.4B 16.56B 6.65B 84.22B 6.33B 6.19B 266B P/E 2026 *
51.3x
P/E 2027 * 17.2x
Enterprise Value 11.25B 13.26B 1.69B 1.51B 1.39B 1.26B 2.36B 160B 2.4B 16.6B 6.66B 84.4B 6.34B 6.21B 266B EV / Sales 2026 *
8x
EV / Sales 2027 * 6.11x
Free-Float
39.57%
Yield 2026 *
-
Yield 2027 * -
1 day-0.46%
1 week-9.03%
1 month-29.45%
3 months+10.74%
6 months-12.25%
Current year-26.17%
1 week 25.2
Extreme 25.2
29.58
1 month 25.2
Extreme 25.2
40.84
Current year 19.22
Extreme 19.22
41.64
1 year 19.22
Extreme 19.22
47.8
3 years 14.8
Extreme 14.8
56.55
5 years 14.8
Extreme 14.8
208
10 years 14.8
Extreme 14.8
450
Manager TitleAgeSince
Corporate Officer/Principal 66 21/02/2024
Chief Tech/Sci/R&D Officer 53 13/01/2009
Chief Executive Officer 62 13/01/2009
Director TitleAgeSince
Chairman 62 13/01/2009
Director/Board Member 63 22/06/2018
Director/Board Member 44 11/10/2021
Date Insider Type Main position Quantity % Market Cap. Importance
26/8/25 Sell

Director

4,600 0.0069%
26/9/24 Other

Chief Executive Officer

20,000 0.0151%
9/9/24 Other

Founder

30,000 0.0226%
Change 5-day change 1-year change 3-year change Capi.($)
-0.46%-9.03%-44.27%+4.16% 1.69B
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +1.83%+4.41%+37.50%+76.52% 426.36B
Weighted average by Cap. +2.01%+6.59%+50.47%+100.40%

Financials

2026 *2027 *
Net sales 1.42B 1.68B 214M 191M 176M 160M 298M 20.29B 304M 2.1B 843M 10.67B 802M 785M 33.66B 1.77B 2.09B 266M 238M 219M 198M 371M 25.24B 378M 2.61B 1.05B 13.28B 998M 976M 41.87B
Net income 111M 130M 16.62M 14.88M 13.69M 12.4M 23.19M 1.58B 23.62M 163M 65.54M 830M 62.37M 61.04M 2.62B 311M 367M 46.78M 41.89M 38.54M 34.92M 65.27M 4.44B 66.49M 460M 184M 2.34B 176M 172M 7.37B
Net Debt 24.02M 28.31M 3.61M 3.23M 2.97M 2.69M 5.04M 343M 5.13M 35.45M 14.23M 180M 13.54M 13.26M 568M -415M -489M -62.37M -55.86M -51.38M -46.55M -87.02M -5.92B -88.65M -613M -246M -3.12B -234M -229M -9.82B
Projected Income Statement - Annual - CanSino Biologics Inc.
Logo CanSino Biologics Inc.
CanSino Biologics Inc is a China-based company primarily engaged in the research and development, production, and commercialization of human vaccine products. The Company’s products and product pipeline under research include multiple vaccine varieties such as meningitis, pneumonia, diphtheria, tetanus, and pertussis (DPT), coronavirus disease 2019 (COVID-19), Ebola virus disease, poliomyelitis, herpes zoster, tuberculosis and others. The Company is also engaged in the research and development of pharmaceutical production processes. The Company conducts its business in the domestic and overseas markets.
Employees
1,134
Date Price Change Volume
30/10/26 HKD 25.78 -0.46% 3,449,400
29/10/26 HKD 25.90 -4.43% 3,937,600
28/10/26 HKD 27.10 -1.53% 8,504,000
27/10/26 HKD 27.52 -5.10% 2,434,628
26/10/26 HKD 29.00 +2.33% 3,209,400
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - CanSino Biologics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
21.87CNY
Average target price
36.48CNY
Spread / Average Target
+66.78%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CanSino Biologics Inc.
  1. Stock Market
  2. Stocks
  3. 6185 Stock